Please enable JavaScript to continue using this application.

Compare $ACRV vs $CTOR | Chartloom

Compare

$ACRV vs $CTOR

Acrivon Therapeutics Inc · Citius Oncology Inc

ACRV

Acrivon Therapeutics Inc

CTOR

Citius Oncology Inc

Compare $ACRV vs $CTOR

Comparing Acrivon Therapeutics Inc and Citius Oncology Inc

ACRVAcrivon Therapeutics Inc

CTORCitius Oncology Inc

ACRVAcrivon Therapeutics Inc

Market cap

$82M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-22.4%

52W performance

1.6%

FCF yield

-78.5%

CTORCitius Oncology Inc

Market cap

$78M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

1.10x

Rev growth (TTM)

—

YTD performance

-22.2%

52W performance

-54.4%

FCF yield

-24.8%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

ACRV

CTOR

Detailed metrics comparison

ACRV

Acrivon Therapeutics Inc

CTOR

Citius Oncology Inc

Market Cap

ACRV$82M

CTOR$78M

Enterprise Value

ACRV$40M

CTOR$72M

Price

ACRV$1.91

CTOR$0.84

P/E Ratio

ACRVN/A

CTORN/A

P/S Ratio

ACRV0.00x

CTOR10.99x

EV/Sales

ACRV0.00x

CTOR10.10x

EV/EBITDA

ACRV0.00x

CTOR0.00x

P/B Ratio

ACRV0.98x

CTOR2.19x

P/FCF Ratio

ACRVN/A

CTORN/A

EV/FCF

ACRV-0.63x

CTOR-3.70x

PEG Ratio

ACRVN/A

CTORN/A

Forward P/E (NTM)

ACRVN/A

CTORN/A

Forward P/S (NTM)

ACRVN/A

CTOR1.10x

Revenue (TTM)

ACRV$0

CTOR$7M

Revenue Growth (YoY)

ACRVN/A

CTORN/A

Forward Rev Growth

ACRV406.9%

CTOR65.4%

Gross Margin (TTM)

ACRV0.0%

CTOR77.3%

Operating Margin (TTM)

ACRV0.0%

CTOR0.0%

EBITDA Margin (TTM)

ACRV0.0%

CTOR-542.8%

Net Margin (TTM)

ACRV0.0%

CTOR-648.3%

FCF Margin (TTM)

ACRVN/A

CTOR-272.9%

Net Income (TTM)

ACRV$-74M

CTOR$-46M

FCF (TTM)

ACRV$-64M

CTOR$-19M

EPS (TTM)

ACRV-$1.77

CTOR-$0.43

ROE (TTM)

ACRV-7014.0%

CTOR-10298.0%

ROA (TTM)

ACRV-6161.0%

CTOR-4349.0%

ROIC (TTM)

ACRV-7014.0%

CTOR-9188.0%

Cash

ACRV$41M

CTOR$17M

Debt

ACRV$0

CTOR$10M

Net Cash/Debt

ACRV$41M

CTOR$6M

Current Ratio (TTM)

ACRV7.99x

CTOR0.73x

Quick Ratio (TTM)

ACRV7.86x

CTOR0.29x

Debt/Equity (TTM)

ACRV0.00x

CTOR0.25x

Debt/Assets (TTM)

ACRV0.0%

CTOR0.0%

Interest Coverage (TTM)

ACRVN/A

CTORN/A

Net Debt/EBITDA (TTM)

ACRV0.00x

CTOR0.00x

Beta

ACRV1.95

CTOR3.34

52W Performance

ACRV1.6%

CTOR-54.4%

YTD Performance

ACRV-22.4%

CTOR-22.2%

% from 52W High

ACRV-46.3%

CTOR-62.7%

% from 52W Low

ACRV50.4%

CTOR71.0%

Asset Turnover (TTM)

ACRV0.00x

CTOR0.00x

FCF Yield (TTM)

ACRV-78.5%

CTOR-24.8%

Earnings Yield (TTM)

ACRV-90.8%

CTOR-59.0%

Dividend Yield (TTM)

ACRVN/A

CTORN/A

Rule of 40

ACRV0.0

CTOR-272.9

EV/GP/RG

ACRVN/A

CTOR0.01

Ticker research

View ACRV research View CTOR research

Metric	ACRV Acrivon Therapeutics Inc	CTOR Citius Oncology Inc
Market & Valuation
Market Cap	$82M	$78M
Enterprise Value	$40M	$72M
Price	$1.91	$0.84
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	10.99x
EV/Sales	0.00x	10.10x
EV/EBITDA	0.00x	0.00x
P/B Ratio	0.98x	2.19x
P/FCF Ratio	N/A	N/A
EV/FCF	-0.63x	-3.70x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	1.10x
Revenue & Growth
Revenue (TTM)	$0	$7M
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	406.9%	65.4%
Profitability
Gross Margin (TTM)	0.0%	77.3%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-542.8%
Net Margin (TTM)	0.0%	-648.3%
FCF Margin (TTM)	N/A	-272.9%
Net Income (TTM)	$-74M	$-46M
FCF (TTM)	$-64M	$-19M
EPS (TTM)	-$1.77	-$0.43
ROE (TTM)	-7014.0%	-10298.0%
ROA (TTM)	-6161.0%	-4349.0%
ROIC (TTM)	-7014.0%	-9188.0%
Financial Health
Cash	$41M	$17M
Debt	$0	$10M
Net Cash/Debt	$41M	$6M
Current Ratio (TTM)	7.99x	0.73x
Quick Ratio (TTM)	7.86x	0.29x
Debt/Equity (TTM)	0.00x	0.25x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.95	3.34
52W Performance	1.6%	-54.4%
YTD Performance	-22.4%	-22.2%
% from 52W High	-46.3%	-62.7%
% from 52W Low	50.4%	71.0%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.00x
FCF Yield (TTM)	-78.5%	-24.8%
Earnings Yield (TTM)	-90.8%	-59.0%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-272.9
EV/GP/RG	N/A	0.01
Ticker research	View ACRV research	View CTOR research

Valuation

P/S Ratio

ACRV

0.00x

CTOR

10.99x

EV/FCF

CTOR

-3.70x

ACRV

-0.63x

Growth & revenue

Forward Revenue Growth

ACRV

406.9%

CTOR

65.4%

Profitability & performance

Gross Margin

CTOR

77.3%

ACRV

0.0%

ROE

ACRV

-7014.0%

CTOR

-10298.0%

FCF Yield %

CTOR

-24.8%

ACRV

-78.5%

52-Week Performance

ACRV

1.6%

CTOR

-54.4%

Detailed metrics comparison

ACRV

Acrivon Therapeutics Inc

CTOR

Citius Oncology Inc

Market Cap

ACRV$82M

CTOR$78M

Enterprise Value

ACRV$40M

CTOR$72M

Price

ACRV$1.91

CTOR$0.84

P/E Ratio

ACRVN/A

CTORN/A

P/S Ratio

ACRV0.00x

CTOR10.99x

EV/Sales

ACRV0.00x

CTOR10.10x

EV/EBITDA

ACRV0.00x

CTOR0.00x

P/B Ratio

ACRV0.98x

CTOR2.19x

P/FCF Ratio

ACRVN/A

CTORN/A

EV/FCF

ACRV-0.63x

CTOR-3.70x

PEG Ratio

ACRVN/A

CTORN/A

Forward P/E (NTM)

ACRVN/A

CTORN/A

Forward P/S (NTM)

ACRVN/A

CTOR1.10x

Revenue (TTM)

ACRV$0

CTOR$7M

Revenue Growth (YoY)

ACRVN/A

CTORN/A

Forward Rev Growth

ACRV406.9%

CTOR65.4%

Gross Margin (TTM)

ACRV0.0%

CTOR77.3%

Operating Margin (TTM)

ACRV0.0%

CTOR0.0%

EBITDA Margin (TTM)

ACRV0.0%

CTOR-542.8%

Net Margin (TTM)

ACRV0.0%

CTOR-648.3%

FCF Margin (TTM)

ACRVN/A

CTOR-272.9%

Net Income (TTM)

ACRV$-74M

CTOR$-46M

FCF (TTM)

ACRV$-64M

CTOR$-19M

EPS (TTM)

ACRV-$1.77

CTOR-$0.43

ROE (TTM)

ACRV-7014.0%

CTOR-10298.0%

ROA (TTM)

ACRV-6161.0%

CTOR-4349.0%

ROIC (TTM)

ACRV-7014.0%

CTOR-9188.0%

Cash

ACRV$41M

CTOR$17M

Debt

ACRV$0

CTOR$10M

Net Cash/Debt

ACRV$41M

CTOR$6M

Current Ratio (TTM)

ACRV7.99x

CTOR0.73x

Quick Ratio (TTM)

ACRV7.86x

CTOR0.29x

Debt/Equity (TTM)

ACRV0.00x

CTOR0.25x

Debt/Assets (TTM)

ACRV0.0%

CTOR0.0%

Interest Coverage (TTM)

ACRVN/A

CTORN/A

Net Debt/EBITDA (TTM)

ACRV0.00x

CTOR0.00x

Beta

ACRV1.95

CTOR3.34

52W Performance

ACRV1.6%

CTOR-54.4%

YTD Performance

ACRV-22.4%

CTOR-22.2%

% from 52W High

ACRV-46.3%

CTOR-62.7%

% from 52W Low

ACRV50.4%

CTOR71.0%

Asset Turnover (TTM)

ACRV0.00x

CTOR0.00x

FCF Yield (TTM)

ACRV-78.5%

CTOR-24.8%

Earnings Yield (TTM)

ACRV-90.8%

CTOR-59.0%

Dividend Yield (TTM)

ACRVN/A

CTORN/A

Rule of 40

ACRV0.0

CTOR-272.9

EV/GP/RG

ACRVN/A

CTOR0.01

Ticker research

View ACRV research View CTOR research

Metric	ACRV Acrivon Therapeutics Inc	CTOR Citius Oncology Inc
Market & Valuation
Market Cap	$82M	$78M
Enterprise Value	$40M	$72M
Price	$1.91	$0.84
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	10.99x
EV/Sales	0.00x	10.10x
EV/EBITDA	0.00x	0.00x
P/B Ratio	0.98x	2.19x
P/FCF Ratio	N/A	N/A
EV/FCF	-0.63x	-3.70x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	1.10x
Revenue & Growth
Revenue (TTM)	$0	$7M
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	406.9%	65.4%
Profitability
Gross Margin (TTM)	0.0%	77.3%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-542.8%
Net Margin (TTM)	0.0%	-648.3%
FCF Margin (TTM)	N/A	-272.9%
Net Income (TTM)	$-74M	$-46M
FCF (TTM)	$-64M	$-19M
EPS (TTM)	-$1.77	-$0.43
ROE (TTM)	-7014.0%	-10298.0%
ROA (TTM)	-6161.0%	-4349.0%
ROIC (TTM)	-7014.0%	-9188.0%
Financial Health
Cash	$41M	$17M
Debt	$0	$10M
Net Cash/Debt	$41M	$6M
Current Ratio (TTM)	7.99x	0.73x
Quick Ratio (TTM)	7.86x	0.29x
Debt/Equity (TTM)	0.00x	0.25x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.95	3.34
52W Performance	1.6%	-54.4%
YTD Performance	-22.4%	-22.2%
% from 52W High	-46.3%	-62.7%
% from 52W Low	50.4%	71.0%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.00x
FCF Yield (TTM)	-78.5%	-24.8%
Earnings Yield (TTM)	-90.8%	-59.0%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-272.9
EV/GP/RG	N/A	0.01
Ticker research	View ACRV research	View CTOR research